All In Biotech

Drug Trial Radar · NCT01460693

Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia

A Phase III, Prospective Randomised Comparison of Imatinib (STI571, Glivec/Gleevec) 400mg Daily Versus Dasatinib 100mg in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia

Last checked: Nov 19, 2026Latest source record: Apr 24, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 814 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

814

Actual

Start

Aug 2008

Primary completion

Mar 7, 2018

Study completion Mar 7, 2018

Sponsor

Lead sponsor
Newcastle UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Newcastle-upon-Tyne Hospitals NHS Trust; Bristol-Myers Squibb; Institute of Cancer Research, United Kingdom; Hammersmith Hospitals NHS Trust
First posted
Oct 27, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Imatinib 400mg daily is the current NICE-approved standard treatment for newly diagnosed Chronic Myeloid Leukaemia (CML). 5 yr follow up of CML patients treated in this way indicates an 89% probability of progression-free survival. Imatinib is not tolerated or effective in some patients however, and a proportion of patients become resistant to the drug. SPIRIT 2 study aims to establish whether a new drug, dasatinib, is superior to imatinib in terms of event free survival and therefore will be an effective first-line therapy for newly-diagnosed CML patients. This study will also provide crucial long-term survival, quality of life and health economic data to assist health care providers and managers to determine the most cost-effective drug therapy for CML.

Conditions

  • Myeloid Leukemia, Chronic, Chronic Phase

Interventions

  • ImatinibDrug

    Oral Imatinib 100mg daily

  • DasatinibDrug

    Oral Dasatinib 100mg daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 5-year event free survivalTime frame: ongoing throughout study (5 years)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Freeman Hospital

    Newcastle upon Tyne, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.